ORIC Pharmaceuticals, Inc. – NASDAQ:ORIC
ORIC Pharmaceuticals stock price today
$9.53
+1.27
+15.52%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
ORIC Pharmaceuticals stock price monthly change
-17.99%
month
ORIC Pharmaceuticals stock price quarterly change
-17.99%
quarter
ORIC Pharmaceuticals stock price yearly change
-9.74%
year
ORIC Pharmaceuticals key metrics
Market Cap | 585.00M |
Enterprise value | 163.83M |
P/E | -2.37 |
EV/Sales | N/A |
EV/EBITDA | -1.91 |
Price/Sales | N/A |
Price/Book | 1.02 |
PEG ratio | 0.27 |
EPS | -1.8 |
Revenue | N/A |
EBITDA | -113.30M |
Income | -101.76M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeORIC Pharmaceuticals stock price history
ORIC Pharmaceuticals stock forecast
ORIC Pharmaceuticals financial statements
| Jun 2023 | 0 | -22.94M | |
|---|---|---|---|
| Sep 2023 | 0 | -25.47M | |
| Dec 2023 | 1.53M | -28.33M | -1842% |
| Mar 2024 | 0 | -25.01M |
| Dec 2023 | 1.53M | -28.33M | -1842% |
|---|---|---|---|
| Mar 2024 | 0 | -25.01M | |
| Oct 2025 | 0 | -32.55M | |
| Dec 2025 | 0 | -33.67M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 291816000 | 23.01M | 7.89% |
|---|---|---|---|
| Sep 2023 | 274335000 | 26.92M | 9.81% |
| Dec 2023 | 254686000 | 30.59M | 12.01% |
| Mar 2024 | 350786000 | 22.14M | 6.31% |
| Jun 2023 | -21.14M | -19.31M | 85.17M |
|---|---|---|---|
| Sep 2023 | -19.64M | -57.83M | 31K |
| Dec 2023 | -24.49M | 20.96M | 680K |
| Mar 2024 | -30.35M | -61.86M | 125.19M |
ORIC Pharmaceuticals alternative data
| Aug 2023 | 88 |
|---|---|
| Sep 2023 | 89 |
| Oct 2023 | 89 |
| Nov 2023 | 89 |
| Dec 2023 | 93 |
| Jan 2024 | 93 |
| Feb 2024 | 93 |
| Mar 2024 | 100 |
| Apr 2024 | 100 |
| May 2024 | 100 |
| Jun 2024 | 102 |
| Jul 2024 | 102 |
ORIC Pharmaceuticals other data
26.88%
-55.93%
of ORIC is owned by hedge funds
29
-36
10.66M
-22.11M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2024 | 0 | 42361 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | PISCITELLI DOMINIC officer: Chief Financial Officer | Common Stock | 8,851 | $8.28 | $73,295 | ||
Sale | MULTANI PRATIK S officer: Chief Me.. | Common Stock | 8,850 | $8.28 | $73,296 | ||
Sale | CHACKO JACOB director, officer: PRESIDENT AN.. | Common Stock | 24,660 | $8.28 | $204,209 | ||
Option | PISCITELLI DOMINIC officer: Chief Financial Officer | Common Stock | 24,042 | N/A | N/A | ||
Option | PISCITELLI DOMINIC officer: Chief Financial Officer | Restricted Stock Unit | 10,000 | N/A | N/A | ||
Option | PISCITELLI DOMINIC officer: Chief Financial Officer | Restricted Stock Unit | 8,000 | N/A | N/A | ||
Option | PISCITELLI DOMINIC officer: Chief Financial Officer | Restricted Stock Unit | 6,042 | N/A | N/A | ||
Option | MULTANI PRATIK S officer: Chief Me.. | Common Stock | 24,042 | N/A | N/A | ||
Option | MULTANI PRATIK S officer: Chief Me.. | Restricted Stock Unit | 10,000 | N/A | N/A | ||
Option | MULTANI PRATIK S officer: Chief Me.. | Restricted Stock Unit | 8,000 | N/A | N/A |
| Patent |
|---|
Application Filling date: 18 Apr 2022 Issue date: 18 Aug 2022 |
Application Filling date: 17 Mar 2022 Issue date: 14 Jul 2022 |
Grant Utility: CD73 inhibitors Filling date: 23 Oct 2020 Issue date: 10 May 2022 |
Application Filling date: 9 Oct 2019 Issue date: 17 Mar 2022 |
Application Filling date: 17 Aug 2021 Issue date: 24 Feb 2022 |
Grant Filling date: 22 Dec 2016 Issue date: 28 Dec 2021 |
Application Filling date: 17 Aug 2021 Issue date: 23 Dec 2021 |
Application Filling date: 21 Jul 2021 Issue date: 9 Dec 2021 |
Grant Utility: CD73 inhibitors Filling date: 17 Mar 2021 Issue date: 28 Sep 2021 |
Grant Utility: CD73 inhibitors Filling date: 9 May 2018 Issue date: 28 Sep 2021 |
| Quarter | Transcript |
|---|---|
| Q4 2021 21 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Jacob M. Chacko M.B.A., M.D. (1979) Pres, Chief Executive Officer & Director | $790,960 |
| Dr. Pratik S. Multani (1967) Chief Medical Officer | $622,290 |
Mr. Dominic G. Piscitelli CPA, M.B.A., CPA (1975) Chief Financial Officer | $568,840 |
ORIC Pharma NSCLC Brain Metastasis Data Is Highly Interesting
Fulcrum Therapeutics: FSHD Steadily Advancing In Phase 3, Optionality With SCD
ORIC Pharma: Small Pfizer Deal, Cash, And A Set Of Very Early Stage Assets
ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech
Insider Weekends: Return Of The Meme Stocks - GameStop And AMC Entertainment
ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas
-
What's the price of ORIC Pharmaceuticals stock today?
One share of ORIC Pharmaceuticals stock can currently be purchased for approximately $9.53.
-
When is ORIC Pharmaceuticals's next earnings date?
Unfortunately, ORIC Pharmaceuticals's (ORIC) next earnings date is currently unknown.
-
Does ORIC Pharmaceuticals pay dividends?
No, ORIC Pharmaceuticals does not pay dividends.
-
How much money does ORIC Pharmaceuticals make?
ORIC Pharmaceuticals has a market capitalization of 585.00M.
-
What is ORIC Pharmaceuticals's stock symbol?
ORIC Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ORIC".
-
What is ORIC Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ORIC Pharmaceuticals?
Shares of ORIC Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ORIC Pharmaceuticals's key executives?
ORIC Pharmaceuticals's management team includes the following people:
- Dr. Jacob M. Chacko M.B.A., M.D. Pres, Chief Executive Officer & Director(age: 46, pay: $790,960)
- Dr. Pratik S. Multani Chief Medical Officer(age: 58, pay: $622,290)
- Mr. Dominic G. Piscitelli CPA, M.B.A., CPA Chief Financial Officer(age: 50, pay: $568,840)
-
How many employees does ORIC Pharmaceuticals have?
As Jul 2024, ORIC Pharmaceuticals employs 102 workers, which is 2% more then previous quarter.
-
When ORIC Pharmaceuticals went public?
ORIC Pharmaceuticals, Inc. is publicly traded company for more then 5 years since IPO on 24 Apr 2020.
-
What is ORIC Pharmaceuticals's official website?
The official website for ORIC Pharmaceuticals is oricpharma.com.
-
Where are ORIC Pharmaceuticals's headquarters?
ORIC Pharmaceuticals is headquartered at 240 East Grand Avenue, South San Francisco, CA.
-
How can i contact ORIC Pharmaceuticals?
ORIC Pharmaceuticals's mailing address is 240 East Grand Avenue, South San Francisco, CA and company can be reached via phone at +65 03885600.
ORIC Pharmaceuticals company profile:
ORIC Pharmaceuticals, Inc.
oricpharma.comExchange:
NASDAQ
Full time employees:
112
Industry:
Biotechnology
Sector:
Healthcare
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
240 East Grand Avenue
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001796280
ISIN: US68622P1093
CUSIP: 68622P109
